- Home
- MPB vs RGNX Comparison
MPB vs RGNX Comparison
Compare MPB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- RGNX
- Stock Information
- Founded
- MPB 1868
- RGNX 2008
- Country
- MPB United States
- RGNX United States
- Employees
- MPB N/A
- RGNX N/A
- Industry
- MPB Major Banks
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPB Finance
- RGNX Health Care
- Exchange
- MPB Nasdaq
- RGNX Nasdaq
- Market Cap
- MPB 467.7M
- RGNX 387.0M
- IPO Year
- MPB N/A
- RGNX 2015
- Fundamental
- Price
- MPB $25.39
- RGNX $5.94
- Analyst Decision
- MPB Buy
- RGNX Strong Buy
- Analyst Count
- MPB 2
- RGNX 8
- Target Price
- MPB $36.00
- RGNX $31.75
- AVG Volume (30 Days)
- MPB 127.4K
- RGNX 1.1M
- Earning Date
- MPB 04-28-2025
- RGNX 05-07-2025
- Dividend Yield
- MPB 3.15%
- RGNX N/A
- EPS Growth
- MPB 26.64
- RGNX N/A
- EPS
- MPB 2.90
- RGNX N/A
- Revenue
- MPB $177,648,000.00
- RGNX $83,328,000.00
- Revenue This Year
- MPB $19.07
- RGNX $285.14
- Revenue Next Year
- MPB $11.53
- RGNX N/A
- P/E Ratio
- MPB $8.76
- RGNX N/A
- Revenue Growth
- MPB 9.01
- RGNX N/A
- 52 Week Low
- MPB $19.20
- RGNX $5.04
- 52 Week High
- MPB $33.87
- RGNX $17.99
- Technical
- Relative Strength Index (RSI)
- MPB 48.00
- RGNX 42.51
- Support Level
- MPB $23.78
- RGNX $5.04
- Resistance Level
- MPB $25.51
- RGNX $6.83
- Average True Range (ATR)
- MPB 1.08
- RGNX 0.61
- MACD
- MPB 0.15
- RGNX -0.05
- Stochastic Oscillator
- MPB 77.90
- RGNX 37.32
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.